AIDS drug for Africa gets final
clearance [http://www.PoliticsWatch.com Updated 5:35 p.m., September
|The final hurdle has been cleared allowing a
Canadian generic drug company to send copies of a patented
drug cocktail to Rwanda.
OTTAWA — Canadian
generic drug company Apotex has been given the final go ahead to
deliver a patented HIV/AIDS drug cocktail to Rwanda.
On Thursday the Federal Commissioner of Patents issued
a compulsory licence for ApoTriavir under Canada's Access to Medicines Regime
(CAMR). The existing patents are held by Glaxo Smith Kline, Shire and
The CAMR program, which was created to allow generic drug companies
to sell copies of patented drugs to developing nations, had been
coming under fire over the last year because it failed to deliver a
single pill since Parliament passed the legislation in 2004.
Last year, Health Minister Tony Clement announced a review of
the program and the Commons industry committee held hearings into
problems with the program this spring.
"Canada is very proud to be the first country to grant a compulsory
license under the August 2003 WTO waiver," Health
Canada told PoliticsWatch in a statement.
"This is an important milestone with regard to access to medicines in the developing world
and we hope that this not only results in affordable HIV medicines being available in
Rwanda, but also helps us to better understand how CAMR may be used to most effectively advance this humanitarian
Apotex will now sell 260,000 packs of the drug cocktail to Rwanda
over the next two years.
Critics of the CAMR program, including Apotex, provided a lukewarm
response to the news, noting that the granting of a compulsory
licence doesn't fix existing problems with the program.
"It's taken over three years just to get this close to filling a single
order for a single drug," said Richard Elliot, executive
director of the Canadian HIV/AIDS Legal Network. "Even if this order goes through, there's clearly a
lot that's wrong with the regime."
In an interview with PoliticsWatch, NDP MP Brian Masse, who
sits on the Commons industry committee, said the new development
doesn't change the concerns he has with the program.
"It doesn't take away from some of the systemic problems we
still have with the bill," he said. "The real issue here
is whether or not we're going to have a system that will meet the
goals of what Canada wanted and I still think there's going to be
problems in the system to do that."
Masse listed the problems as recipient countries being required to
identify themselves, the small number of drugs that are eligible for
the program and how CIDA and Health Canada's
promote the program in the developing world.
© PoliticsWatch® 2007. All rights reserved. Republication
or redistribution of PoliticsWatch content, including by framing,
copying, linking or similar means, is expressly prohibited without
the prior written consent of Public Interests Research and Communications
Inc. (PIRCINC). PoliticsWatch is registered trademark of PIRCINC.